These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23401175)

  • 21. Measuring the bioactivity and molecular conformation of typically globular proteins with phenothiazine-derived methylene blue in solid and in solution: A comparative study using photochemistry and computational chemistry.
    Ding F; Xie Y; Peng W; Peng YK
    J Photochem Photobiol B; 2016 May; 158():69-80. PubMed ID: 26950891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MSUT2 is a determinant of susceptibility to tau neurotoxicity.
    Guthrie CR; Greenup L; Leverenz JB; Kraemer BC
    Hum Mol Genet; 2011 May; 20(10):1989-99. PubMed ID: 21355046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress and developments in tau aggregation inhibitors for Alzheimer disease.
    Bulic B; Pickhardt M; Mandelkow E
    J Med Chem; 2013 Jun; 56(11):4135-55. PubMed ID: 23484434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assays for the Screening and Characterization of Tau Aggregation Inhibitors.
    Rickard JE; Horsley D; Wischik CM; Harrington CR
    Methods Mol Biol; 2017; 1523():129-140. PubMed ID: 27975248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau protein and tau aggregation inhibitors.
    Bulic B; Pickhardt M; Mandelkow EM; Mandelkow E
    Neuropharmacology; 2010; 59(4-5):276-89. PubMed ID: 20149808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls.
    Ayyadevara S; Balasubramaniam M; Parcon PA; Barger SW; Griffin WS; Alla R; Tackett AJ; Mackintosh SG; Petricoin E; Zhou W; Shmookler Reis RJ
    Aging Cell; 2016 Oct; 15(5):924-39. PubMed ID: 27448508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.
    Sun W; Lee S; Huang X; Liu S; Inayathullah M; Kim KM; Tang H; Ashford JW; Rajadas J
    Sci Rep; 2016 Oct; 6():34784. PubMed ID: 27708431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Zecca C; Barulli MR; Bellomo A; Pilotto A; Daniele A; Greco A; Logroscino G
    Biomed Res Int; 2016; 2016():3245935. PubMed ID: 27429978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GSK3: a possible link between beta amyloid peptide and tau protein.
    Hernández F; Gómez de Barreda E; Fuster-Matanzo A; Lucas JJ; Avila J
    Exp Neurol; 2010 Jun; 223(2):322-5. PubMed ID: 19782073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice.
    Hosokawa M; Arai T; Masuda-Suzukake M; Nonaka T; Yamashita M; Akiyama H; Hasegawa M
    PLoS One; 2012; 7(12):e52389. PubMed ID: 23285020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidation of phenothiazine and phenoxazine by Cunninghamella elegans.
    Sutherland JB; Freeman JP; Heinze TM; Moody JD; Parshikov IA; Williams AJ; Zhang D
    Xenobiotica; 2001 Nov; 31(11):799-809. PubMed ID: 11765142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative regulation of fatty acid-induced tau polymerization.
    Gamblin TC; King ME; Kuret J; Berry RW; Binder LI
    Biochemistry; 2000 Nov; 39(46):14203-10. PubMed ID: 11087369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of human tau 3D structure, and interplay between O-β-GlcNAc and phosphorylation modifications in Alzheimer's disease: C. elegans as a suitable model to study these interactions in vivo.
    Ahmad W; Shabbiri K; Ahmad I
    Biochem Biophys Res Commun; 2020 Jul; 528(3):466-472. PubMed ID: 32499112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.
    McCormick AV; Wheeler JM; Guthrie CR; Liachko NF; Kraemer BC
    Biol Psychiatry; 2013 Mar; 73(5):464-71. PubMed ID: 23140663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oleuropein and derivatives from olives as Tau aggregation inhibitors.
    Daccache A; Lion C; Sibille N; Gerard M; Slomianny C; Lippens G; Cotelle P
    Neurochem Int; 2011 May; 58(6):700-7. PubMed ID: 21333710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments.
    Barghorn S; Mandelkow E
    Biochemistry; 2002 Dec; 41(50):14885-96. PubMed ID: 12475237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppressing Tau Aggregation and Toxicity by an Anti-Aggregant Tau Fragment.
    Pir GJ; Choudhary B; Kaniyappan S; Chandupatla RR; Mandelkow E; Mandelkow EM; Wang Y
    Mol Neurobiol; 2019 May; 56(5):3751-3767. PubMed ID: 30196394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics.
    Pritchard SM; Dolan PJ; Vitkus A; Johnson GV
    J Cell Mol Med; 2011 Aug; 15(8):1621-35. PubMed ID: 21348938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards Asymmetrical Methylene Blue Analogues: Synthesis and Reactivity of 3-
    Khadieva A; Rayanov M; Shibaeva K; Piskunov A; Padnya P; Stoikov I
    Molecules; 2022 May; 27(9):. PubMed ID: 35566375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.
    Jouanne M; Rault S; Voisin-Chiret AS
    Eur J Med Chem; 2017 Oct; 139():153-167. PubMed ID: 28800454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.